Budget impact of Vonaprument
4 evidence topics · 15 sources
Summary: price and economic evidence status
Vonaprument is investigational, and the sponsor states that it does not “have any products approved for sale”. No price, wholesale acquisition cost, average sales price, or HCPCS code for vonaprument has been published, and no cost-effectiveness analysis, budget impact model, or health technology assessment of vonaprument was identified. The phase 3 ARCHER II trial, ongoing in 659 participants, tests monthly vonaprument 5.0 mg per eye. As of the latest source, the sponsor's third-quarter 2026 results press release, ARCHER II had reported no results: an independent Data Monitoring Committee “will assess the ARCHER II single study Month 15 primary endpoint in the fourth quarter of 2026”, with results of the two pre-specified sub-studies “anticipated in the first quarter of 2027” if the endpoint is met, and ARCHER II completion “expected in the third quarter of 2027”. The single study is to be analyzed for an EU filing and the two sub-studies for a U.S. filing.
The sponsor states that it has “established a small commercial organization and have not established distribution capabilities”, that it has “not yet engaged any manufacturers for the commercial supply” of its product candidates, and that there is no assurance that a product “will be considered cost-effective by third-party payors”.
Summary: company estimate of the treated population
In a statement that begins “Based on market reports”, the sponsor estimates that approximately 75,000 patients in the United States are actively treated with available therapies, about 10% of the 800,000 people diagnosed with geographic atrophy or under the care of retina specialists and about 5% of a U.S. population with geographic atrophy of 1.5 million. The sponsor's Form 10-K gives a different prevalence figure, stating that geographic atrophy affects “more than an estimated one million people in the United States and eight million people worldwide”.
Summary: comparator costs and utilization
- Medicare Part B payment limits for October to December 2026 were $135.267 per 1 mg billing unit of pegcetacoplan (Syfovre, J2781), an “AMP-based payment limit”, and $100.563 per 0.1 mg billing unit of avacincaptad pegol (Izervay, J2782).
- At launch in 2023, the list price was $2,190 per vial for Syfovre and $2,100 per vial for Izervay.
- The national non-facility Medicare payment for an intravitreal injection (CPT 67028) was $114.23 in 2026, an increase of 4.79% from $109.01 in 2025.
- Medicare Part B spending on pegcetacoplan was $76,651,580.03 for 17,414 beneficiaries in 2023, $403,855,394.80 for 29,338 beneficiaries (148,576 claims) in 2024, $451,069,360.05 for 32,021 beneficiaries (168,366 claims) in 2025, and $109,568,082.68 for 24,179 beneficiaries (41,654 claims) in the first quarter of 2026.
- Medicare Part B spending on avacincaptad pegol was $190,365,232.80 for 18,308 beneficiaries (73,172 claims) in 2024, $364,934,587.10 for 27,497 beneficiaries (140,741 claims) in 2025, and $105,232,261.84 for 23,315 beneficiaries (41,264 claims) in the first quarter of 2026; the annual dataset reports no 2023 values for this product.
Summary: published comparator economic evaluations
A U.S. analysis based on 2022 Medicare reimbursement data, with outcomes extrapolated from the DERBY and OAKS trials, reported 2-year costs to treat geographic atrophy with pegcetacoplan of $70,000 with every-month (EM) dosing and $34,600 with every-other-month (EOM) dosing, and costs per quality-adjusted life-year (QALY) gained, based on modeled visual loss with 95% atrophy, of $706,000 (EM) and $397,000 (EOM). A second analysis based on 2022 Medicare reimbursement data reported 2-year costs of $67,400 (EM) and $40,600 (EOM) for avacincaptad pegol; for extrafoveal geographic atrophy, the facility-based cost per mm2 of retinal pigment epithelium saved was $119,000 (EM) and $57,100 (EOM) with avacincaptad pegol versus $54,000 (EM) and $31,400 (EOM) with pegcetacoplan (P < 0.001 for both comparisons). A de novo U.S. cost-utility model of pegcetacoplan that included the costs and utility loss of informal caregiving reported $77,735 per QALY gained over a lifetime with costs and benefits discounted at 3.5%, and $55,806 per QALY gained for lesions at least 250 μm from the foveal center.
In Australia, the Pharmaceutical Benefits Advisory Committee (PBAC) assessed cost-utility analyses of both products versus best supportive care over 20 years. For pegcetacoplan, multivariate analyses increased the base case ICER from $45,000 to < $55,000 to $95,000 to < $115,000 per QALY gained; the PBAC considered an ICER in the order of $55,000 to < $75,000 per QALY gained acceptable, stated that a price reduction would be required, and considered the amended financial estimates reasonable “as the basis of a risk sharing arrangement”. For avacincaptad pegol, a multivariate analysis increased the base case ICER from $55,000 to < $75,000 to $115,000 to < $135,000 per QALY gained; the PBAC considered an ICER in the order of $45,000 to < $55,000 per QALY gained acceptable, noted that a price reduction would be required, and advised a cost-minimisation approach against pegcetacoplan should pegcetacoplan proceed to listing.
The PBAC financial estimates for pegcetacoplan were a cost to the PBS/RPBS of $50 million to < $60 million in year 6 and $200 million to < $300 million over the first 6 years of listing. For avacincaptad pegol, the submission estimated $20 million to < $30 million in year 1, increasing to $60 million to < $70 million in year 6, and $300 million to < $400 million over the first 6 years; in scenario analyses of continued monthly dosing after year 1, the ESC noted that the year 6 estimate increased to $70 million to < $80 million. The NICE appraisal of pegcetacoplan was suspended after information provided by the company in February 2025 and has been discontinued.